Headquartered in India, Dr Reddy’s is a global, vertically integrated pharmaceutical company with a presence across the value chain, producing and delivering safe, innovative, and high quality finished dosage forms, APIs and biological products.
Their products are marketed across the globe, with an emphasis on North America, Europe, India, Russia and other emerging markets. Dr Reddy's conduct NCE drug discovery research in the areas of metabolic disorders and cardiovascular indications at our research facilities in Atlanta (USA) and Hyderabad (India).
Through their Custom Pharmaceutical Services business unit, they provide drug substance and drug product development and manufacturing services on a proprietary basis.
About the Audit
Dr Reddys Laboratories Ltd Unit 6 was audited between 7 - 8 Februaury 2008. The Report is 43 pages long, excluding appendices. Including appendices, the Report is 98 pages long.
The Audit Report provides information on the site facilities and covers a wide range of materials, including; Amtolmetion Gaucil, Balaglitazone, Carvedilol Phosphate, Clopidogrel Bisulphate, Pafuuramidine Maleate, Dextromethorphan, Dextromethorphan Hydrobromide, Desloratadine, Dilitazem Hydrochloride, Divalproex Sodium, Domperidone, Domperidone Maleate, Duloxetine Hydrochloride, Esozopiclone, Fluconazole, Fosphenytoin Sodium, Flecainide Acetate, Ibuprofen, Irbesartan, Ibandronate Sodium, Loratadine, Levetriacetam, Liarozole Fumarate, Lansoprazole, Naratriptan Hydrochloride, Nateglinide, Nizatidine, Olmesartan Medoxomil, Oxaprozin, Oxcarbazepine, Pioglitazone Hydrochloride, Primidone, Quetiapine Fumarate, Rambazole, Sertaline Hydrochloride, Sulindac, Risedronate Sodium Hemipentahydrate, Tolterodine Tartrate, Valsartan, Venlafaxine Hydrochloride, Valacyclovir Hydrochloride, Zafarlukast Amorphous and also the Organic intermediate: ECPA.